Insights
Search Results
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
11.04.25
Firm Advises Automation Anywhere on Acquisition of Aisera
On November 4, 2025, Automation Anywhere, the leading provider of Agentic Process Automation (APA) and agentic solutions, announced it has acquired Aisera, the leading provider of agentic solutions for autonomous IT. The acquisition expands Automation Anywhere’s deep AI portfolio and expertise in automating mission-critical enterprise processes with Aisera’s industry-leading self-service agents for IT Service Management (ITSM), HR, and Customer Service—creating the industry’s most comprehensive agentic automation portfolios to deliver autonomous operations across departments and improve employee and customer experience. Wilson Sonsini Goodrich & Rosati advised Automation Anywhere on the transaction.
Client Highlights
6.30.25
Wilson Sonsini Advises Portal Biotech on IP Matters Related to $35 Million Series A Financing
On June 30, 2025, Portal Biotech, a pioneering biotechnology company based in London, announced a $35 million Series A financing round—one of the largest investments in a life sciences tools company in Europe. The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with participation from existing investors Science Creates Venture Capital, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank, and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Portal Biotech on IP diligence matters related to the transaction.
Client Highlights
2.21.25
Wilson Sonsini Advises Anaerobe Systems on Acquisition by Biolog
On February 12, 2025, Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, announced the acquisition of Anaerobe Systems. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies. Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction.
Client Highlights
2.18.25
Wilson Sonsini Advises Esperto Medical on Oversubscribed Series A
On February 18, 2025, Esperto Medical™, a healthtech start-up specializing in critical care and remote patient monitoring, announced the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures. Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction.
Client Highlights
10.02.24
Wilson Sonsini Advises Pure Lithium on Asset Acquisition of Dimien
On October 1, 2024, Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announced the acquisition of all the assets of Dimien Inc., a private U.S. vanadium cathode materials company. Pure Lithium acquired Dimien’s intellectual property, know-how, and manufacturing equipment. Dimien's experienced team will also join the company. Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction.
Client Highlights
8.22.24
Firm Advises Novo Holdings on IP Matters Related to Oxford Nanopore Investment
On August 1, 2024, Novo Holdings, a leading international life science investor, announced a £50 million investment in Oxford Nanopore Technologies, a leading UK-listed company behind a new generation of molecular sensing technology based on nanopores, which is today used for DNA/RNA sequencing. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on IP diligence matters related to the transaction.
Client Highlights
5.29.24
Wilson Sonsini Advises Radar Therapeutics on IP Matters Related to $13.4 Million Seed Funding
On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.
Client Highlights
5.28.24
Wilson Sonsini Advises Mirus Bio and Gamma Bio on Patent Matters Related to $600 Million Sale
On May 23, 2024, Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash. Wilson Sonsini Goodrich & Rosati advised Mirus Bio and Gamma Bio on patent matters related to the transaction.
Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN® GMP and RevIT™ AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.
Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN® GMP and RevIT™ AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.
News Articles
5.24.24
Wilson Sonsini Sponsors National Inventors Hall of Fame Induction Ceremony
On May 9, 2024, the National Inventors Hall of Fame held its annual Induction Ceremony in Washington, D.C., to celebrate the latest class of inductees who have made exceptional contributions to society. Wilson Sonsini Goodrich & Rosati was a visionary sponsor of the event, which was hosted in partnership with the United States Patent and Trademark Office. Sir Shankar Balasubramanian, founder of Solexa (acquired by Illumina in 2007) and firm client Biomodal, was honored among the 2024 inductees. Numerous Wilson Sonsini patents and innovation practitioners were in attendance, including partners Vern Norviel, Lou Lieto, Ali Alemozafar, and Derrick Rowe; senior patent counselor Bruce Kisliuk; and senior counsel Jeff Seidel, as well as chief licensing advisor Kathy Ku.
Client Highlights
5.08.24
Wilson Sonsini Advises Pascal on IP Matters Related to $8 Million Seed Round
On May 8, 2024, Pascal, a start-up developing high-efficiency climate-friendly heat pumps, air conditioners, and refrigerators based on solid refrigerants, introduced its novel technology and announced it has raised an $8 million seed round led by Engine Ventures, with Khosla Ventures and previous investor Blindspot Ventures participating. The funding will be used to productize Pascal’s low pressure, solid refrigerant-based system, conforming to commercial HVAC specifications. The company will also use the capital to expand its Boston-based team of mechanical engineers, chemists, and material scientists. Pascal launched from the Mason Group at Harvard University, a research group led by Jarad Mason in the Department of Chemistry and Chemical Biology that applies the tools of coordination chemistry, materials science, and nanotechnology to design materials that address science challenges in energy and medicine.
Client Highlights
3.14.24
Wilson Sonsini Advises Pure Lithium on $15 Million Series A
On March 14, 2024, Pure Lithium, a disruptive Boston-based lithium metal battery technology company, announced the completion of a $15 million Series A financing led by Oxy Low Carbon Ventures, a subsidiary of Occidental. Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction. The capital infusion will accelerate Pure Lithium's development and commercialization efforts.